There is currently limited literature assessing the real-world treatment patterns and clinical outcomes of patients with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) mutations. Medical charts were abstracted for mCRPC patients with ≥ 1 of 12 HRR somatic gene alterations treated at US oncology centers participating in the American Association for Cancer Research Project Genomics Evidence Neoplasia Information Exchange. Treatment patterns and clinical outcomes were assessed from the initiation of first-line or later (1L+) mCRPC therapy received on or after July 1, 2014. Among 138 patients included in the study, the most common somatic HRR mutations were (47.8%), (22.5%), and (21.0%). Novel hormonal therapy and taxane chemotherapy were most commonly used in 1L; taxane use increased in later lines. Median overall survival (95% confidence interval [CI]) was 36.3 (30.7-47.8) months from initiation of 1L therapy and decreased for subsequent lines. Similarly, there was a trend of decreasing progression-free survival and prostate-specific antigen response from 1L to 4L+ therapy. Treatment patterns identified in this study were similar to those among patients with mCRPC regardless of tumor HRR mutation status in the literature.

中文翻译：

---

携带同源重组修复突变的转移性前列腺癌患者的治疗模式和临床结果

目前评估转移性去势抵抗性前列腺癌（mCRPC）和同源重组修复（HRR）突变患者的现实治疗模式和临床结果的文献有限。为参加美国癌症研究协会基因组学证据肿瘤信息交换的美国肿瘤中心治疗的 12 个 HRR 体细胞基因改变中≥1 个的 mCRPC 患者提取了医学图表。从 2014 年 7 月 1 日或之后接受的一线或后期 (1L+) mCRPC 治疗开始评估治疗模式和临床结果。在该研究纳入的 138 名患者中，最常见的体细胞 HRR 突变为 (47.8%)， （22.5%）和（21.0%）。新型激素疗法和紫杉烷类化疗最常用于1L；后来的系列中紫杉烷的使用有所增加。从 1L 治疗开始起，中位总生存期（95% 置信区间 [CI]）为 36.3 (30.7-47.8) 个月，后续线路有所下降。同样，从 1L 治疗到 4L+ 治疗，无进展生存期和前列腺特异性抗原反应有降低的趋势。无论文献中肿瘤 HRR 突变状态如何，本研究中确定的治疗模式与 mCRPC 患者的治疗模式相似。